Peptide Sciences thymosin alpha 1 is sold as a research-use-only peptide. Learn what the label means, typical research dosing, safety notes, and legal status.
Peptide Sciences thymosin alpha 1 is a research-use-only form of thymalfasin, a synthetic 28-amino-acid peptide that has been studied as an immune modulator for more than three decades. Peptide Sciences sells it as a lyophilized powder intended for laboratory research, not as a prescription drug, so the vial arrives with no approved human dosing instructions and no FDA clearance for medical use. Understanding that distinction is the most important thing for anyone searching this combination of terms.
What Is Thymosin Alpha 1?
Thymosin alpha 1 is a peptide originally isolated from thymosin fraction 5, a bovine thymus extract, and it is now produced synthetically. It is the same molecule sold in several countries as the prescription drug Zadaxin.
In laboratory and clinical research, thymosin alpha 1 is described as acting on both innate and adaptive immunity. Researchers report that it binds to Toll-like receptors on dendritic cells, supports T-cell maturation, and shifts cytokine activity toward a Th1-type response.
It has been studied in hepatitis B and C, sepsis, oncology support, and vaccine-adjuvant settings. Results have been mixed, and larger trials have not always confirmed the benefits seen in smaller ones.
How Peptide Sciences Lists and Labels It
In the Peptide Sciences catalog, thymosin alpha 1 typically appears as a lyophilized white powder in sealed glass vials, commonly listed in multi-milligram quantities.
- Labeled "for research use only — not for human consumption"
- Shipped with a certificate of analysis (COA) showing purity and molecular mass
- Usually accompanied by HPLC and mass spectrometry data
- Requires refrigerated or frozen storage, especially after reconstitution
None of that is a dosing guide. A research label describes what the compound is, not how a person should use it.
Is Peptide Sciences Thymosin Alpha 1 FDA Approved?
No. Peptide Sciences thymosin alpha 1 is not FDA-approved for human use, because the FDA has never cleared thymalfasin for any indication in the United States. In countries where thymosin alpha 1 peptide therapy is prescribed, the drug is marketed as Zadaxin and is typically given as a subcutaneous injection, often alongside standard antiviral treatment.
Anything sold as a research chemical in the US cannot legally carry disease-treatment claims, and buyers should treat marketing language that promises outcomes as a red flag.
That does not automatically make the product illegal to purchase. Selling and possessing research peptides for laboratory use is generally permitted, but using them in humans falls outside that framework, and state laws vary.
Thymosin Alpha 1 Benefits and Side Effects Reported in Research
What the studies suggest
Most of what gets described as thymosin alpha 1 benefits comes from small trials, animal models, and laboratory work. Reported areas of interest include:
- Improved immune response in chronic hepatitis B and C when combined with antiviral therapy
- Possible reductions in mortality or secondary infection in some sepsis and post-surgical studies
- Stronger vaccine response in older or immunocompromised patients
- Immune support during cancer treatment, usually as an add-on rather than a primary therapy
These findings are not consistent across trials, and none of them establish thymosin alpha 1 as a cure for any condition in the United States.
Side effects and safety
Reported thymosin alpha 1 side effects are usually mild and short-lived. Injection-site reactions, fatigue, muscle aches, and low-grade fever are the most commonly described.
Serious reactions appear to be rare, but research peptides carry an extra risk that prescription drugs do not: purity, sterility, and actual peptide content depend entirely on the supplier. A mislabeled or contaminated vial can cause harm that has nothing to do with the molecule itself.
Anyone considering use should talk with a licensed healthcare professional first, especially people who are pregnant, immunocompromised, or taking immunosuppressant medication.
Thymosin Alpha 1 Dosage Chart From Published Studies
The table below summarizes doses reported in published clinical literature. These are study protocols administered under medical supervision, not recommendations for self-administration.
| Research setting | Reported dose | Route | Frequency |
|---|---|---|---|
| Chronic hepatitis B (registered use) | 1.6 mg | Subcutaneous | Twice weekly |
| Sepsis trials | 1.6 mg | Subcutaneous | Every 12 hours for 5 days, then daily for 5 days |
| Oncology support studies | 0.9–1.6 mg | Subcutaneous | Daily to 2–3 times weekly |
| Immunology and vaccine studies | 1.6 mg or 900 mcg/m² | Subcutaneous | Twice weekly or single dose |
Any thymosin alpha 1 dosage chart circulating online should be read as a summary of research, not as a personal plan. Dose, timing, and duration in a real clinical setting depend on the condition, the patient's immune status, and what other drugs are involved.
Comparing Vendors and Vetting a Batch
Peptide Sciences is one of several suppliers in a crowded market. Buyers often compare aod 9604 peptide sciences and epithalon peptide sciences listings at the same time, and the differences between products in a single catalog are mostly about format, listed size, and documentation rather than medical purpose.
| Research peptide | Typical listed size | Common research focus | US regulatory status |
|---|---|---|---|
| Thymosin alpha 1 | 5–10 mg vial | Immune modulation | Not FDA-approved |
| AOD 9604 | 2–5 mg vial | Metabolic and fat-metabolism research | Not FDA-approved |
| Epithalon | 10 mg vial | Telomerase and aging research | Not FDA-approved |
Before buying from any vendor, check these items:
- A third-party COA with a batch number that matches the vial
- HPLC purity above 95 percent, plus a mass spectrometry result
- Clear research-use-only labeling with no human dosing claims
- Disclosed shipping and storage conditions
- Responsive customer support and a published refund policy
A low price usually means less testing, not a better deal. Purity documentation is the only thing separating a research peptide from an unknown powder.
Peptide Sciences thymosin alpha 1 is a synthetic immune-modulating peptide sold for laboratory research, and it is not FDA-approved for human use in the United States. The research base is real but mixed, and most human data comes from studies conducted outside the US under medical supervision. Anyone weighing personal use should consult a physician and treat supplier quality as seriously as the molecule itself.
Frequently Asked Questions
Is Peptide Sciences thymosin alpha 1 legal to buy in the United States?
Research peptides labeled for laboratory use only can generally be sold and purchased in the US for research purposes. That label does not authorize human consumption, so buying the vial to inject is outside its intended use and carries both legal and health risks. State laws vary, and buyers should check local regulations before ordering.
Is thymosin alpha 1 FDA approved?
No. Thymosin alpha 1 (thymalfasin) is not FDA-approved for any indication in the United States. It is approved as a prescription medicine in several other countries under the brand name Zadaxin. US buyers typically encounter it only as a research-use-only peptide.
What thymosin alpha 1 dosage is used in studies?
Published clinical trials most often used 1.6 mg subcutaneously twice weekly, while some sepsis and oncology protocols used 1.6 mg daily or every 12 hours for short courses. Those figures come from supervised clinical research and are not self-dosing recommendations. A qualified clinician should determine any dose used in humans.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.